Vebreltinib Receives NMPA Approval in China for MET Fusion+

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

Related Keywords

China , Chin Neurosurg , Guo Liang Yu , World Health Organization , Apollomics Inc , China National Medical Products Administration , National Medical Products Administration , Karnofsky Performance Status , Global Oncology , News , Brain Cancer ,